Evidence map›Paper›PMID 40712009›Full record

ArticleScience advances2025

Genetically engineered chondrocyte-mimetic nanoplatform attenuates osteoarthritis by blocking IL-1β and restoring sirtuin-3.

Caifeng Deng, Liukang Yu, Xuan Zhao, Yuxiao Chen, Jiabin Mei, Jie Wei, Xiaoyuan Chen, Guanghua Lei, Chao Zeng

Abstract read
In one paragraph

Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Caifeng DengDepartment of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China.ORCID 0000-0002-0153-5168
Liukang YuDepartment of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China.ORCID 0009-0001-2413-4957
Xuan ZhaoDepartment of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China.
Yuxiao ChenDepartment of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China.
Jiabin MeiDepartment of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China.
Jie WeiDepartment of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China.ORCID 0000-0003-3510-8241
Xiaoyuan ChenDepartment of Diagnostic Radiology, Yong Loo Lin School of Medicine and College of Design and Engineering, National University of Singapore, Singapore, Singapore.ORCID 0000-0002-9622-0870
Guanghua LeiDepartment of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China.ORCID 0000-0003-2987-138X
Chao ZengDepartment of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China.ORCID 0000-0003-4889-5731

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoarthritis (OA) is a multifactorial disease characterized by joint inflammation and cartilage degeneration, with no disease-modifying drugs available. The vicious cycle between the inflammatory microenvironment (inflamed soil) and dysfunctional chondrocytes (degeneration-related seeds) drives the chronic progressive deterioration of OA. Here, we report a genetically engineered chondrocyte-mimetic nanoplatform (termed HKL-GECM@MPNPs) comprising a honokiol (HKL)-loaded mitochondrion-targeting nanoparticle core coated with an interleukin-1 receptor type 2 (IL-1R2)-overexpressing chondrocyte membrane. HKL-GECM@MPNPs fuse with OA chondrocytes, transferring IL-1R2 onto the plasma membrane and reprogramming the inflamed microenvironment through IL-1β blockade. Mitochondrion-targeting cores then directly deliver HKL to restore mitochondrial sirtuin-3 in OA chondrocytes, reprogramming the cells' pathological phenotype. Intra-articular injection of HKL-GECM@MPNPs in OA mice reduces inflammation, alleviates joint pain, and mitigates cartilage damage through a synergistic effect. Moreover, HKL-GECM@MPNPs effectively reverse cartilage degeneration in human OA cartilage explants. This approach highlights the potential of HKL-GECM@MPNPs to combine IL-1β blockade and mitochondrial sirtuin-3 restoration as a promising strategy for OA treatment.

Indexed as

ChondrocytesGenetic EngineeringInterleukin-1betaNanoparticlesOsteoarthritisSirtuin 3Allyl CompoundsAnimalsBiphenyl CompoundsDisease Models, AnimalHumansLignansMaleMiceMitochondriaPhenolsAllyl CompoundsBiphenyl CompoundshonokiolInterleukin-1betaLignansPhenolsSirtuin 3

Identifiers

PMID40712009
PMCPMC12292748

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.